Origami Therapeutics is making strides in neurodegenerative disease treatment by leveraging autophagy to target misfolded proteins in the brain. Founded by Dr. Beth Hoffman, the biotech company aims to restore proper protein structure or eliminate harmful proteins, with a focus on conditions like Huntington’s, Alzheimer’s, and Parkinson’s diseases. Their recent collaboration with Ipsen will enhance their protein degrader program, addressing inherited neurodegenerative disorders and aiming to alter disease progression fundamentally.

This innovative approach is significant as it tackles the root causes of neurodegeneration, particularly disruptions in protein homeostasis, rather than merely alleviating symptoms. By employing phenotypic screening and targeting the autophagy-lysosome pathway, Origami seeks to develop small molecules that can effectively address a broader range of proteins, including those previously deemed “undruggable.” This strategy not only has implications for neurodegenerative diseases but may also extend to other aging-related conditions.

For professionals in the longevity field, Origami’s work highlights the potential of precision medicine in restoring cellular balance and improving healthspan. To dive deeper into Dr. Hoffman’s insights and the company’s innovative strategies, I recommend reading the full article.

Source: longevity.technology